Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 8/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | DKK1 | O94907 | 3/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | TTK | P33981 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4535467 | 0.85 | IKBKB (0.53) | IKBKBHDAC8DKK1MAPK10RET | |
| SCHEMBL3643870 | 0.84 | MAPK10 (0.58) | IKBKBHDAC8DKK1MAPK10RET | |
| SCHEMBL3651275 | 0.84 | IKBKB (0.72) | IKBKBHDAC8DKK1MAPK10 | |
| SCHEMBL3647354 | 0.84 | CYP11B2 (0.58) | IKBKBHDAC8DKK1MAPK10AURKA | |
| SCHEMBL3648299 | 0.83 | MAPK10 (0.60) | IKBKBHDAC8MAPK10RETADORA2A | |
| SCHEMBL3650816 | 0.83 | HDAC8 (0.52) | IKBKBHDAC8DKK1MAPK10ADORA2A | |
| SCHEMBL3643856 | 0.82 | HDAC8 (0.51) | IKBKBHDAC8DKK1MAPK10AURKA | |
| SCHEMBL3648663 | 0.82 | HDAC8 (0.51) | IKBKBHDAC8DKK1MAPK10AURKA | |
| SCHEMBL3653157 | 0.81 | HDAC8 (0.55) | IKBKBHDAC8DKK1MAPK10AURKA | |
| SCHEMBL3648269 | 0.81 | DKK1 (0.58) | IKBKBHDAC8DKK1MAPK10RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WNT1, CTNNB1, WNT3A | IKBKB 1022/4885HDAC8 1830/4885DKK1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.